Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Share-based Compensation (2016 - 2025)

Palisade Bio (PALI) has disclosed Share-based Compensation for 16 consecutive years, with $202000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 78.76% to $202000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$226000.0, a 175.59% decrease, with the full-year FY2024 number at $135000.0, changed N/A from a year prior.
  • Share-based Compensation was $202000.0 for Q3 2025 at Palisade Bio, up from -$69000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $569000.0 in Q1 2021 to a low of -$428000.0 in Q4 2024.
  • A 5-year average of $150800.0 and a median of $129000.0 in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 649.75% in 2021, then plummeted 153.49% in 2025.
  • Palisade Bio's Share-based Compensation stood at $495000.0 in 2021, then plummeted by 82.63% to $86000.0 in 2022, then soared by 123.26% to $192000.0 in 2023, then plummeted by 322.92% to -$428000.0 in 2024, then surged by 147.2% to $202000.0 in 2025.
  • Per Business Quant, the three most recent readings for PALI's Share-based Compensation are $202000.0 (Q3 2025), -$69000.0 (Q2 2025), and $69000.0 (Q1 2025).